NeuroPace, Inc. (NASDAQ:NPCE) Short Interest Down 27.0% in April
March 30th total of 637,100 shares. Based on an average daily volume of 517,400 shares, the short-interest ratio is presently 0.9 days. NeuroPace saw a 27% decline in short interest in April.
() experienced a significant decline in short interest during the month of March. On April 30, there were 467,700 short shares. This is a decrease of 27,0% from April 15th's total of 640 800 shares. The days-to-cover is currently 17.7 days based on an average trading volume (26,400 shares). About 5.6% of a company's stock is sold short.
Inflows of Institutional Capital and Outflows
Several hedge fund and institutional investors recently increased or decreased their stakes in NPCE. FMR LLC increased its holdings in NeuroPace during the first quarter by 3.0%. FMR LLC owns 1,492,931 of the company stock, valued at $6.927,000, after purchasing 43,005 additional shares during the last quarter. SG Americas Securities LLC acquired a new share of NeuroPace in the first quarter for $118,000. Soleus Capital Management L.P. increased its holdings in NeuroPace during the fourth-quarter by 1.5%. Soleus Capital Management L.P. owns 2,369 003 shares worth $3,530,000, after buying an additional 35,000 in the fourth quarter. Millennium Management LLC increased its stake in NeuroPace in the fourth-quarter by 18.2%. Millennium Management LLC owns 691 899 shares worth $1,031,000, after buying 106 532 shares in the last quarter. Morgan Stanley increased its holdings of NeuroPace in the fourth-quarter by 3.1%. Morgan Stanley now has 2,188,593 of the company’s shares worth $3,261,000, after adding 64,990 more shares during the last quarter. NPCE has been the subject of several analyst opinions. Lake Street Capital started covering NeuroPace on Wednesday, 22nd February in a research report. The stock was given a buy' rating with a target price of $10.00. Morgan Stanley increased their price target for shares of NeuroPace to $4.50 from $2.50 in a research report on Friday, 3rd March.
NeuroPace Trading down 4.3 %
On Friday, the stock fell $0.19 to $4.26. 8252 shares were traded, compared with the average volume of 27771 for this company. The company's current ratio is 9.13, its quick ratio is 8.04, and it has a debt to equity ratio of 1.96. The market cap is $108.23m, the PE ratio is -2.29, and beta is 2.53. The 50-day moving price of the stock is $4.45, and its 200 day moving price is $3.34. NeuroPace's 52-week low is $1.22, and its 52-week high is $6.53.
The company last released its earnings on Thursday, 2nd March. The company's ($0.45) per-share earnings for the third quarter beat analysts' consensus estimates ($0.49) ($0.49) by $0.04. NeuroPace's negative return on equity was 116.02%, and its negative net margin was 94.61%. During the third quarter, revenue was $12.79million. Analysts at Equities Research predict that NeuroPace's EPS will be -1.79 for the current fiscal year.
NeuroPace, Inc is a medical devices company that operates in the United States. It sells RNS System, a brain responsive neuromodulation system that treats medically refractory foci epilepsy with personalized real-time treatments at the source of seizures. RNS, the company's system for recording continuous brain activity data and monitoring patients remotely and in person.
MarketBeat.com offers a FREE daily email newsletter